Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,1 USD | -4,43% | -6,82% | -40,36% |
16/04 | SAB Biotherapeutics, Inc. Geeft SAB-142 Proefupdate | CI |
02/04 | SAB BIOTHERAPEUTICS, INC. : HC Wainwright nog altijd een koopadvies | ZM |
Vakgebied
Aantal werknemers: 57
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Immunotheraphies
100,0
%
| 24 | 100,0 % | 2 | 100,0 % | -90,63% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 24 | 100,0 % | 2 | 100,0 % | -90,63% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 22-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 22-10-21 |
Michael King
DFI | Director of Finance/CFO | 63 | 30-10-23 |
Christoph Bausch
COO | Chief Operating Officer | 53 | 01-03-17 |
Chief Tech/Sci/R&D Officer | 51 | 06-06-22 | |
Melissa Ullerich
IRC | Investor Relations Contact | - | 01-03-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 68 | 22-10-21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 22-10-21 |
Erick Lucera
BRD | Director/Board Member | 57 | 03-04-23 |
David Link
BRD | Director/Board Member | 69 | 22-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 22-10-21 |
William Polvino
BRD | Director/Board Member | 63 | 22-10-21 |
Eddie Sullivan
FOU | Founder | 58 | 22-10-21 |
Andrew Moin
BRD | Director/Board Member | - | 05-10-23 |
Katie Ellias
BRD | Director/Board Member | - | 20/11 |
Scott Giberson
BRD | Director/Board Member | - | 11-07-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 9 280 160 | 7 460 413 ( 80,39 %) | 54 666 ( 0,5891 %) | 80,39 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-40,36% | 37,82 mln. | |
-1,94% | 104 mld. | |
+3,97% | 97,47 mld. | |
+5,65% | 22,25 mld. | |
-13,69% | 21,68 mld. | |
-9,44% | 18,2 mld. | |
-39,98% | 17,02 mld. | |
-11,77% | 16,36 mld. | |
+6,80% | 14,39 mld. | |
+38,77% | 12,37 mld. |
- Beurs
- Aandelen
- Koers SABS
- Onderneming SAB Biotherapeutics, Inc.